 Shares of Myovant Sciences soared 27 Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and womens health in a deal worth up to 4.2 billion in upfront and potential milestone payments. 